Access cutting-edge hpv treatment through this clinical trial at a research site in Baltimore. Study-provided care at no cost to qualified participants.
Access hpv specialists in Baltimore at no cost
This study follows strict safety protocols and ethical guidelines
All study-related hpv treatment provided free
This is a phase 2, open-label study to assess the immunogenicity of the 9-valent human papillomavirus (HPV) recombinant vaccine (Gardasil9) in people born male with current or past exposure to androgen blockers or estrogen (BM-EABE). Investigators will enroll BM-EABE with HIV and HIV negative controls (BM-EABE or men who have sex with a person with a penis (MSPP)) and administer Gardasil9 at timepoints Day 0, Month 2, and Month 6. The immune response to the vaccine will be analyzed at Month 7 (1
Sponsor: University of Maryland, Baltimore
Check if you qualify for this hpv clinical trial in Baltimore, MD
If you're searching for hpv treatment options in Baltimore, MD, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Baltimore research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hpv specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.